Lento Bio Relocates to Syracuse, NY, Joining Ichor Life Sciences’ New Biotech Incubator Facility
SYRACUSE, NY, USA, June 3, 2024 /EINPresswire.com/ — Lento Bio, a preclinical pharmaceutical startup focused on developing eyedrops for the treatment of presbyopia, announced today its relocation from Potsdam, NY to Syracuse, NY. The move comes as part of Ichor Life Sciences’ expansion into a new facility in downtown Syracuse, which will serve as a […]
Lento Bio Announces Official Collaboration With Florida State University and Expansion of Advisory Board
POTSDAM, NY, USA, February 7, 2023/EINPresswire.com- Lento Bio, an early-stage pharmaceutical research company developing novel small molecule drugs for presbyopia, is proud to announce two major points of progress in assembling the technical and scientific expertise required to further development of its novel pipeline focused on presbyopia and other diseases of aging. These include an […]
Lento Bio Raises $680,000 In Oversubscribed Seed Round Led by Ichor Life Sciences
POTSDAM, NY / September 6, 2022 / Lento Bio, Inc., a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near-vision in presbyopia patients, announced today they have raised $680,000 in funding during their recent oversubscribed seed round. Ichor Life Sciences is the lead investor for the round, providing $400,000 in funding to Lento Bio. […]
Lento Bio Appoints Two Ichor Life Sciences Executives as Members of The Board of Directors and Scientific Advisors
Potsdam, N.Y. – Lento Bio, Inc., a preclinical pharmaceutical company developing therapeutics to target molecular damage driving age-related disease, announced today it appointed Dr. Kelsey Moody, PhD, MBA, CEO, and founder of Ichor Life Sciences as a member of its board of directors. Lento Bio also appointed Dr. Moody and Dr. Aaron Wolfe, PhD and […]
Lento Bio, An Ichor Life Sciences Portfolio Company, Launches With Aims to Develop Anti-Glycation Drugs for Presbyopia and Diseases of Aging
Potsdam, N.Y. –. Lento Bio, Inc., a preclinical pharmaceutical company focused on developing small-molecule therapeutics to target molecular damage driving age-related disease, announced its launch today. The company will initially focus on developing pharmaceutical eyedrops to treat a common vision disorder, presbyopia, or age-related farsightedness. Lento Bio will be supported and incubated by Ichor Life […]